Core Insights - Ken-Valve, a transcatheter aortic valve replacement (TAVR) product developed by the company, has successfully completed its first commercial implants in key hospitals across China, marking a significant milestone in its commercialization process [1][2] - The product is designed to treat severe aortic regurgitation or combined aortic stenosis, addressing a critical clinical need in the market for TAVR products [1] - The design features of Ken-Valve, including a one-piece clamping positioning key and an active bending delivery system, enhance valve stability and coaxiality during implantation, catering to patients with complex anatomical structures [1] Market Strategy - The successful launch of Ken-Valve signifies the initiation and smooth advancement of its commercial application in China, prompting the company to expand its sales network and pursue global commercialization of its core products, including the Ken-Valve and LuX-Valve series [2] - The company aims to optimize production costs and operational efficiency to achieve its revenue targets as soon as feasible [2]
健世科技-B(09877.HK)：Ken-Valve成功完成首批商业化植入